Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | LDLR | P01130 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 4/20 | 0.40 |
| ▸ | HTR7 | P34969 | 4/20 | 0.40 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4980851 | 0.78 | IDO1 (0.51) | IDO1KDM4EALDH1A1HPGDHTR2C | |
| SCHEMBL3710027 | 0.70 | HTR2C (0.61) | IDO1KDM4ECYP1A2HTR2CLDLR | |
| SCHEMBL7812363 | 0.70 | CYP1A2 (0.60) | KMT2AKDM4EALDH1A1MEN1CYP1A2 | |
| SCHEMBL30800794 | 0.69 | KDM4E (0.59) | KMT2AKDM4EALDH1A1MEN1PDE10A | |
| SCHEMBL4979885 | 0.69 | IDO1 (0.48) | IDO1KDM4EALDH1A1HPGDHTR2C | |
| SCHEMBL14499332 | 0.69 | KDM4E (0.59) | KMT2AKDM4EALDH1A1MEN1PDE10A | |
| SCHEMBL5422717 | 0.69 | KDM4E (0.58) | IDO1KMT2AKDM4EALDH1A1MEN1 | |
| SCHEMBL1269455 | 0.69 | KMT2A (0.58) | KMT2AKDM4EALDH1A1MEN1CYP1A2 | |
| SCHEMBL23499966 | 0.69 | KDM4E (0.51) | KMT2AKDM4EALDH1A1MEN1CYP1A2 | |
| SCHEMBL23499968 | 0.69 | MEN1 (0.47) | KMT2AKDM4EALDH1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1363993-A4 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | BRISTOL MYERS SQUIBB CO (US) | 2008-11-12 | — | — | EP | disclosed |
| EP-1325009-B1 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL MYERS SQUIBB CO (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6960585-B2 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-01 | — | — | US | disclosed |
| US-6869956-B2 | Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-22 | — | — | US | disclosed |
| EP-1363993-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK) | Bristol-Myers Squibb Company (US) | 2003-11-26 | — | — | EP | disclosed |
| EP-1325009-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2003-07-09 | — | — | EP | disclosed |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | BRISTOL-MYERS SQUIBB COMPANY | 2003-01-30 | — | — | US | disclosed |
| WO-2002060386-A2 | METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-08 | — | — | WO | disclosed |
| US-20020072523-A1 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-13 | — | — | US | disclosed |
| WO-2002028860-A2 | AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020072523-A1 | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | IL4, IL4I1, MSR1 | IDO1 46/4885KMT2A 2115/4885KDM4E 595/4885 |
| US-20030022898-A1 | Methods of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK) | NFKBIA, IKBKG, IKBKB | IDO1 28/4885KMT2A 616/4885KDM4E 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.